

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技术有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

**RESULTS OF THE SPECIAL GENERAL MEETING
HELD ON JANUARY 16, 2024**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”) is pleased to announce that, on January 16, 2024, the Company held its special general meeting (the “**SGM**”) at which all the ordinary resolutions set out in the notice of special general meeting (the “**Notice**”) dated December 22, 2023 were duly passed by way of poll.

Reference is made to the circular (the “**Circular**”) of the Company dated December 22, 2023 in respect of the Share Purchase Agreement and the discloseable and connected transaction contemplated thereunder and the non-exempt continuing connected transactions contemplated under the Exclusive Services Framework Agreement and the Notice. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE SGM

The Board is pleased to announce that at the SGM held at Forum Room 1, B2/F, Regal Hongkong Hotel, 88 Yee Wo Street, Causeway Bay, Hong Kong on Tuesday, January 16, 2024 at 2:30 p.m., all the ordinary resolutions set out in the Notice (the “**Resolutions**”) were duly passed by way of poll. The poll results in respect of the Resolutions were as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
1(a)	the share purchase agreement entered into between the Company and Taobao Holding Limited on November 28, 2023 (the “ Share Purchase Agreement ”) and the connected transaction contemplated thereunder be and are hereby approved, confirmed and ratified; and	2,075,262,639 (99.99%)	8 (0.01%)
1(b)	any one or more of the directors of the Company (the “ Directors ”) for and on behalf of the Company, be and are hereby authorized to sign, seal, execute and deliver all such documents and deeds, and do all such acts, matters and things as they may in their discretion consider necessary, desirable or expedient to give effect to and/or to implement the transactions contemplated in resolution 1(a).	2,075,262,639 (99.99%)	8 (0.01%)
2(a)	subject to the passing of resolutions no. 1(a) and 1(b) and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited granting the listing of, and permission to deal in, the 2,558,222,222 Shares in aggregate as consideration under the Share Purchase Agreement (the “ Consideration Shares ”), the grant of a specific mandate to the Directors with the power and authority to allot and issue the Consideration Shares to Taobao Holding Limited in accordance with the terms of the Share Purchase Agreement be and are hereby approved; and	2,053,327,547 (98.94%)	21,935,100 (1.06%)

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
2(b)	any one or more of the Directors for and on behalf of the Company, be and are hereby authorized to sign, seal, execute and deliver all such documents and deeds, and do all such acts, matters and things as they may in their discretion consider necessary, desirable or expedient to give effect to and/or to implement the transactions contemplated in resolution 2(a).	2,075,262,647 (100.00%)	0 (0.00%)
3(a)	subject to the passing of resolutions no. 1(a) and (b), the non-exempt continuing connected transactions contemplated under the exclusive services framework agreement entered into between Hangzhou Jingzhun Health Information Technology Co., Ltd.* (杭州精準健康信息科技有限公司) and Hangzhou Alimama Software Services Co., Ltd.* (杭州阿里媽媽軟件服務有限公司) on November 27, 2023 and the proposed annual caps for the years ending March 31, 2024, 2025 and 2026, be and are hereby approved, confirmed and ratified; and	2,075,262,647 (100.00%)	0 (0.00%)
3(b)	any one or more of the Directors for and on behalf of the Company, be and are hereby authorized to sign, seal, execute and deliver all such documents and deeds, and do all such acts, matters and things as they may in their discretion consider necessary, desirable or expedient to give effect to and/or to implement the transactions contemplated in resolution 3(a).	2,075,262,647 (100.00%)	0 (0.00%)

Notes:

- (1) The full text of the Resolutions is set out in the Notice.
- (2) To the best knowledge, belief and information of the Directors, as at the date of the SGM:
 - (a) without taking into account any Consideration Shares to be issued as a result of the completion of the Share Purchase Agreement, the total number of Shares in issue was 13,533,514,042 as at the date of the SGM. Since the last monthly return submitted by the Company under Rule

13.25B of the Listing Rules, the Company had issued a total of 14,500 Shares due to the exercise of share options by certain employees of the Company under the Company's share award scheme. Such share options were not exercised by a Director and hence a next day disclosure return was not submitted by the Company under Rule 13.25A(1) of the Listing Rules. Following the SGM and the passing of the Resolutions, the Company will proceed to Completion in accordance with the Share Purchase Agreement and an additional 2,558,222,222 Shares will be issued to Taobao Holding Limited (the Vendor) as Consideration Shares. Following the issuance of the Consideration Shares, the total number of Shares in issue will increase to 16,091,736,264;

- (b) Perfect Advance Holding Limited, Alibaba Investment Limited, Ali JK Nutritional Products Holding Limited and their respective associates (including Antfin (Hong Kong) Holding Limited), which hold a total of 7,773,894,533 Shares, representing approximately 57.44% of the issued share capital of the Company, have abstained from voting at the SGM. The trustee of the share award scheme held 1,972,100 and 3,121,058 Shares for the CP Trust Account and the NCP Trust Account, respectively, representing approximately 0.015% and 0.023% of the issued share capital of the Company, respectively. Pursuant to Rule 17.05A of the Listing Rules, the trustee has abstained from voting on all of the Resolutions at the SGM. Save as disclosed above, no other Shareholder is required to abstain from voting on the Resolutions contemplated thereunder;
 - (c) save as disclosed above, none of the Shareholders was required to attend and abstain from voting on the Resolutions at the SGM pursuant to Rule 13.40 of the Listing Rules. None of the Shareholders has stated in the Circular his/her/its intention to vote against or to abstain from voting on any of the Resolutions at the SGM;
 - (d) the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the SGM was 5,754,526,351; and
 - (e) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the SGM was nil.
- (3) The Directors that attended the SGM were Mr. Zhu Shunyan, Mr. Shen Difan, Mr. Tu Yanwu, Ms. Huang Jiaojiao, Mr. Xu Haipeng, Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong.
 - (4) Tricor Secretaries Limited, was appointed as the scrutineer at the SGM for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of each of the Resolutions, all the Resolutions were duly passed as ordinary resolutions of the Company.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
ZHU Shunyan
Chairman

Hong Kong, January 16, 2024

As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.

** English name for identification purposes only*